Opinion|Videos|February 25, 2025
Patient Voices: Shaping the Future of PNH Care
Author(s)David Dingli, MD, PhD, Brandi Lewis
Panelists discuss how their lived experiences and insights as patients should inform research priorities, treatment development, and care delivery improvements while sharing hopes for a future cure that would eliminate ongoing disease management needs and allow greater life flexibility.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What role do you think patient voices should play in guiding future advancements in paroxysmal nocturnal hemoglobinuria (PNH) care?
- How do you imagine your life might change if there were a cure for PNH in the future?
This program was made possible with support from Novartis Pharmaceuticals.
Advertisement
Related to this article
At The Liver Meeting 2026, Daniel Q. Huang, MBBS, PhD, explained why cirrhosis-based HCC surveillance misses many patients with MASLD and how to find them.
At The Liver Meeting 2026, Hashem B. El-Serag, MD, MPH, discussed when patients with MASLD and F3 fibrosis may merit HCC surveillance.
At The Liver Meeting 2026, Pierre Gholam, MD, explained why liver tumor board plans often break down at implementation and how navigators can help.
Surveillance guidelines limited to cirrhosis may miss up to a third of patients with MASLD-related HCC, according to Daniel Q. Huang, MBBS, PhD.
Hashem B. El-Serag, MD, MPH, discussed fibrosis-based HCC surveillance, ultrasound limits, chemoprevention, and alcohol screening for patients with MASLD.
At The Liver Meeting® 2026, Andrew Moon, MD, MPH, discussed research revealing gaps between clinician and patient priorities in HCC treatment choice.
Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.
In the VERIFY trial, rusfertide produced a clinical response in 77% of phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC
2
Tambiciclib Combo Shows Activity in Relapsed/Refractory Post-Venetoclax AML
3
What Separates a Next-Generation Liver Tumor Board From the Traditional Model?
4
MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance
5